The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis

The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis

Background: The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC). Subsequent analysis demonstrated that low tumour burden and indolent disease are good prognosis factors improving progression-free survival (PFS) and overall survival (OS). T...

Full description

Bibliographic Details
Main Authors:	M.João de Sousa, Inês Gomes, Tatiana Cunha Pereira, Joana Magalhães, Raquel Basto, Judy Paulo, Paula Jacinto, Nuno Bonito, Gabriela Sousa
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Cancer Treatment and Research Communications
Subjects:	Colorectal cancer Chemotherapy Trifluridine/tipiracil Prognostic factor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468294222000223

Similar Items

Trifluridine–tipiracil plus bevacizumab versus trifluridine–tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-06-01)

Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01)

Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study
by: Yukiya Narita, et al.
Published: (2024-06-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
by: T. Sakakida, et al.
Published: (2024-09-01)

Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer
by: Yoshitaka Saito, et al.
Published: (2024-11-01)

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer
by: K. Fukuda, et al.
Published: (2024-03-01)

Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country
by: Lana Jajac-Bručić, et al.
Published: (2021-01-01)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
by: Meng-Che Hsieh, et al.
Published: (2022-05-01)

Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report
by: Bülent Karabulut, et al.
Published: (2024-06-01)

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context
by: Lene Baeksgaard Jensen, et al.
Published: (2024-04-01)

Eco-friendly HPTLC method for Trifluridine and Tipiracil determination: Quality-by-design meets green analytical chemistry
by: Amruta Balekundri, et al.
Published: (2025-06-01)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
by: Celia Lara-Morga, et al.
Published: (2023-04-01)

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
by: M. Yu. Fedyanin
Published: (2020-12-01)

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
by: Keigo Chida, et al.
Published: (2021-03-01)

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
by: Stefan Kasper, et al.
Published: (2018-11-01)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
by: Naoki Takahashi, et al.
Published: (2023-08-01)

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
by: Yongli Hu, et al.
Published: (2024-07-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases
by: Nicholas Fidelman, et al.
Published: (2022-12-01)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
by: G. Sommerhäuser, et al.
Published: (2022-07-01)

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
by: Daniel Sur, et al.
Published: (2022-10-01)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024-11-01)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
by: Mohamed ELBassiouny
Published: (2023-03-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
by: Taruba Rais, et al.
Published: (2024-07-01)

Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme
by: Timothy Iveson, et al.
Published: (2020-02-01)

Applicable Pharmacokinetic Study: Development and Validation of Bioanalytical LC-MS/MS Method for Simultaneous Determination of Tipiracil, Trifluridine and Its Two Metabolites 5-Trifluoromethyluracil, 5-Carboxy 2′-Deoxyuridine in Rat Plasma
by: Manal El-Gendy, et al.
Published: (2023-12-01)

Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
by: Ruohong Lin, et al.
Published: (2024-12-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
by: Linde Kehmann, et al.
Published: (2023-05-01)

TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al.

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion
by: Stefano Cascinu, et al.
Published: (2022-12-01)

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
by: Takeshi Kawakami, et al.
Published: (2022-06-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

Analysis of microarray-identified genes and MicroRNAs associated with Trifluridine resistance in colorectal cancer
by: Qiqi Zhang, et al.
Published: (2022-12-01)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
by: Daichi Watanabe, et al.
Published: (2023-11-01)

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab
by: Masatsune Shibutani, et al.
Published: (2025-01-01)